Chronic kidney disease remains one of the most prevalent and clinically challenging disorders in geriatric feline patients. Although fluid therapy, nutritional management, and blood pressure control form the backbone of treatment, clinicians continue to seek adjunctive strategies that target the pathophysiology of disease progression. Increasing evidence implicates oxidative stress as a key driver of renal injury in cats with CKD. Consequently, antioxidant therapies deserve careful evaluation in acute decompensated chronic kidney disease.
A recent double-blind, placebo-controlled clinical trial investigated the impact of intravenous N-acetylcysteine on renal biomarkers in cats experiencing acute exacerbations of naturally occurring CKD. The findings provide important insights for veterinary professionals managing these complex patients.
Oxidative Stress and Feline CKD Pathophysiology
Oxidative stress reflects an imbalance between reactive oxygen species production and antioxidant defense mechanisms. In kidney tissue, particularly metabolically active tubular cells, mitochondrial density and high oxygen consumption increase vulnerability to oxidative injury. Previous studies have demonstrated that cats with CKD exhibit measurable oxidative stress abnormalities. Reactive oxygen species contribute to:
- Lipid peroxidation
- DNA damage
- Mitochondrial dysfunction
- Inflammatory signaling
- Progressive nephron loss
Given this mechanistic framework, therapies that replenish intracellular glutathione or directly scavenge free radicals may offer renoprotective benefits.
Study Design: NAC in Acute-on-Chronic Kidney Disease
The referenced study enrolled 50 client-owned cats with IRIS stage 2–4 azotemic CKD and ultrasonographic evidence of chronic structural renal changes. Importantly, these cats presented with acute clinical decompensation characterized by vomiting, anorexia, polyuria, polydipsia, lethargy, and dehydration.
Cats were randomized to:
- NAC group (n=40): 70 mg/kg IV N-acetylcysteine diluted in 50 mL saline IV q12 hr for 7 days
- Placebo group (n=10): 50 mL saline IV q12 hr for 7 days
All cats received intravenous fluid therapy with Ringer solution based on estimated dehydration of 6–8%. No additional medications were administered during the study period. Bloodwork and urinalysis were repeated on day 8. This design allowed direct comparison of NAC plus fluids versus fluids alone in acute decompensated CKD.
Effects on Renal Biomarkers
The study demonstrated statistically significant improvements in multiple kidney function biomarkers in the NAC group compared with placebo.
Symmetric Dimethylarginine
Both groups experienced decreases in SDMA. However, day 8 SDMA concentrations were significantly lower in the NAC group:
- NAC: 16.5 ± 1.21 µg/dL
- Placebo: 27 ± 3.89 µg/dL
- P = 0.04
Because SDMA reflects early changes in glomerular filtration rate and rises before creatinine in feline CKD, this finding suggests meaningful improvement in GFR biomarkers beyond fluid therapy alone.
Serum Creatinine
Creatinine decreased in both groups. Nevertheless, the reduction was significantly greater with NAC:
- NAC: 4.01 ± 0.25 mg/dL
- Placebo: 6.44 ± 0.9 mg/dL
- P < 0.001
These data indicate enhanced recovery of filtration markers in the NAC cohort.
Blood Urea Nitrogen
BUN decreased significantly in the NAC group but not in the placebo group. Given BUN is influenced by hydration status and catabolism, this selective improvement strengthens the argument that NAC provided additional renal support beyond volume correction.
Urine Protein to Creatinine Ratio
Proteinuria decreased significantly in the NAC group, while no change occurred in the placebo group. Reduction in UPC may reflect improved glomerular integrity or decreased oxidative inflammatory injury.
Safety Profile and Tolerability
No adverse effects were reported during the 7-day intravenous administration period. All cats survived to discharge. Hospitalization duration was comparable between groups, though slightly shorter in the NAC cohort. These findings suggest short-term intravenous NAC at 70 mg/kg was well tolerated in azotemic cats with acute decompensation.
Mechanistic Rationale for NAC in Feline CKD
N-acetylcysteine acts primarily as a precursor to glutathione, the major intracellular antioxidant. It also exerts anti-inflammatory and anti-apoptotic effects. Proposed renal mechanisms include:
- Enhancement of glutathione synthesis
- Reduction of mitochondrial oxidative damage
- Attenuation of tubular apoptosis
- Suppression of inflammatory mediators such as IL-6
- Potential improvement in renal hemodynamics
Experimental and human studies support NAC’s role in reducing creatinine, BUN, and proteinuria in various renal injury models. This feline clinical trial extends those findings to naturally occurring CKD with acute decompensation.
Clinical Implications for Veterinary Practice
While fluid therapy remains foundational in acute decompensated CKD, this study suggests intravenous NAC may enhance short-term improvement in renal biomarkers when added to standard care.
Key clinical takeaways:
- NAC at 70 mg/kg IV twice daily for 7 days was well tolerated
- Significant reductions occurred in SDMA, creatinine, BUN, and UPC
- Biomarker improvements exceeded those seen with fluids alone
- The intervention targeted oxidative stress, a known contributor to CKD progression
However, clinicians should interpret these findings within context. The study evaluated short-term biomarker response. It did not assess long-term survival, progression rate, or sustained renal function after discharge. Additionally, cats across IRIS stages 2–4 were included, which introduces heterogeneity. Therefore, NAC should be viewed as a promising adjunctive therapy rather than a replacement for established CKD management strategies such as dietary modification, phosphorus control, blood pressure management, and proteinuria modulation.
Future Directions in Feline Nephrology
This trial represents one of the first clinical evaluations of NAC in naturally occurring feline CKD. Larger multicenter trials with extended follow-up would clarify:
- Durability of biomarker improvement
- Impact on progression to advanced IRIS stages
- Effects on hospitalization frequency
- Influence on quality of life and survival
Moreover, future research should incorporate oxidative stress biomarkers to directly correlate biochemical changes with antioxidant effects.
Conclusion
N-acetylcysteine in feline acute on chronic kidney disease demonstrates encouraging short-term reductions in creatinine, SDMA, BUN, and proteinuria when administered intravenously alongside fluid therapy. The data support oxidative stress modulation as a viable therapeutic target in decompensated CKD. For veterinary professionals managing complex renal patients, NAC may represent a practical and biologically plausible adjunct during hospitalization for acute exacerbations. Continued investigation will determine whether this intervention alters the long-term trajectory of feline chronic kidney disease.
I am looking for clarification on whether NAC was given every 12 hrs or 24 hrs. The paper says administered intravenously over 7 days. Thanks for educating us.
I was initially confused re: NAC protocol when I first read the paper. I didn’t feel it was very clear. In one sentence, the authors write, “N-acetylcysteine (70 mg/kg, diluted in 50 ml 0.9% saline solution, administered intravenously over a period of 7 days”; then later in the same paragraph, they state “All therapeutic interventions were administered twice daily for a period of one week at the hospital.” So, for clarification, I contacted the PI directly; their response: “The protocol consisted of administering NAC at a dose of 70 mg/kg, diluted in 50 mL of 0.9% saline solution, delivered intravenously every 12 hours for a total duration of 7 days.” I hope this additional information helps!
Is the effect of nac given po the same?
That is a good question, one that requires more research to answer.